Supplementary Figure S1 from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases

Supplementary Figure S1 from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases

<p>Gene expression of major signalling pathways and multiplex immunohistochemical comparison of markers between timepoints and tumor sites. A) Gene expression of related oncogenic signalling pathways between treatment timepoints and site, B) Estimated mean difference of proteins and pathways b...

Kaydedildi:

Detaylı Bibliyografya
Yazar:	James S. Wilmott (15008931) (author)
Diğer Yazarlar:	Hussein Tawbi (15054769) (author), Johnathan A. Engh (15054772) (author), Nduka M. Amankulor (15054775) (author), Brindha Shivalingam (15054778) (author), Hiya Banerjee (15054781) (author), Ismael A. Vergara (15054784) (author), Hansol Lee (15054787) (author), Peter A. Johansson (15054790) (author), Peter M. Ferguson (15054793) (author), Philippe Saiag (15054796) (author), Caroline Robert (15032672) (author), Jean-Jacques Grob (15054799) (author), Lisa H. Butterfield (15035537) (author), Richard A. Scolyer (10778711) (author), John M. Kirkwood (15023483) (author), Georgina V. Long (11420813) (author), Michael A. Davies (14932995) (author)
Baskı/Yayın Bilgisi:	2025
Konular:	Cancer Tumor Biology Therapeutic Research and Development Clinical Research and Trials Clinical Trial Results Phase II clinical trials Skin Cancers Melanoma Small Molecule Agents Kinase inhibitors Tumor Microenvironment Immune cells and the microenvironment
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller

Supplementary Tables S1-7 from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases
Yazar:: James S. Wilmott (15008931)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S1 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
Yazar:: Qingsheng Xu (17078830)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S3 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
Yazar:: Qingsheng Xu (17078830)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure 1 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
Yazar:: Tom Wei-Wu Chen (15053003)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure 2 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
Yazar:: Tom Wei-Wu Chen (15053003)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure 3 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
Yazar:: Tom Wei-Wu Chen (15053003)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure 4 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
Yazar:: Tom Wei-Wu Chen (15053003)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table 1 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
Yazar:: Tom Wei-Wu Chen (15053003)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S4 from Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial
Yazar:: Andrés Elía (15055031)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S5 from Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial
Yazar:: Andrés Elía (15055031)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S6 from Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial
Yazar:: Andrés Elía (15055031)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S7 from Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial
Yazar:: Andrés Elía (15055031)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S8 from Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial
Yazar:: Andrés Elía (15055031)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data 1 from Pilot Study of ONCOS-102 and Pembrolizumab: Remodeling of the Tumor Microenvironment and Clinical Outcomes in Anti–PD-1–Resistant Advanced Melanoma
Yazar:: Alexander N. Shoushtari (15023909)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure S1 from Phase I Study of Niraparib in Combination with Radium-223 for the Treatment of Metastatic Castrate-Resistant Prostate Cancer
Yazar:: Zachary Quinn (15052893)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S2 from A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma
Yazar:: John A. Ligon (15024477)
Baskı/Yayın Bilgisi: (2025)

Supplementary Tables S1-S4 from Integrating Tumor-Intrinsic and Immunologic Factors to Identify Immunogenic Breast Cancers from a Low-Risk Cohort: Results from the Randomized SweBCG91RT Trial
Yazar:: Axel Stenmark Tullberg (15029928)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figures S1-S4 from Neoadjuvant Pembrolizumab and Radical Cystectomy in Patients with Muscle-Invasive Urothelial Bladder Cancer: 3-Year Median Follow-Up Update of PURE-01 Trial
Yazar:: Giuseppe Basile (15051269)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data Tables 1 from Immunogenomic Landscape of Neuroendocrine Prostate Cancer
Yazar:: Bhavneet Bhinder (14963342)
Baskı/Yayın Bilgisi: (2025)

Figure S1 from A Phase II Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma <i>In Situ</i> of the Bladder
Yazar:: Roger Li (17078665)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure S1 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
Yazar:: Ulka N. Vaishampayan (15051039)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
Yazar:: Ulka N. Vaishampayan (15051039)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure S3 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
Yazar:: Ulka N. Vaishampayan (15051039)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
Yazar:: Ulka N. Vaishampayan (15051039)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data 1 from Monitoring Sarcoma Response to Immune Checkpoint Inhibition and Local Cryotherapy with Circulating Tumor DNA Analysis
Yazar:: Nam Q. Bui (14958210)
Baskı/Yayın Bilgisi: (2025)

Figure 1 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
Yazar:: Nigel Bundred (15046233)
Baskı/Yayın Bilgisi: (2025)

Figure 2 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
Yazar:: Nigel Bundred (15046233)
Baskı/Yayın Bilgisi: (2025)

Figure 3 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
Yazar:: Nigel Bundred (15046233)
Baskı/Yayın Bilgisi: (2025)

Table 1 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
Yazar:: Nigel Bundred (15046233)
Baskı/Yayın Bilgisi: (2025)

Table 2 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
Yazar:: Nigel Bundred (15046233)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure S1 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
Yazar:: Fabrice Barlesi (15045504)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure S2 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
Yazar:: Fabrice Barlesi (15045504)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure S3 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
Yazar:: Fabrice Barlesi (15045504)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure S4 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
Yazar:: Fabrice Barlesi (15045504)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure S5 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
Yazar:: Fabrice Barlesi (15045504)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure 1 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
Yazar:: Dwight H. Owen (15034782)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure 2 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
Yazar:: Dwight H. Owen (15034782)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure 3 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
Yazar:: Dwight H. Owen (15034782)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure 4 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
Yazar:: Dwight H. Owen (15034782)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure 5 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
Yazar:: Dwight H. Owen (15034782)
Baskı/Yayın Bilgisi: (2025)

Cannot write session to /tmp/vufind_sessions/sess_lo05ha52ecte7lma0pana6l4ig